R esistant hypertension (RH) is defined as blood pressure (BP) above target despite the concurrent use of 3 antihypertensive drugs of different classes prescribed at optimal doses.
R esistant hypertension (RH) is defined as blood pressure (BP) above target despite the concurrent use of 3 antihypertensive drugs of different classes prescribed at optimal doses. 1 RH is a common clinical problem of multifactorial pathogenesis. The prevalence of RH is estimated to be in the range 9% to 12% in the population of adult patients with hypertension, and it is progressively increasing. 2 Because of prolonged exposure to suboptimal BP control, RH is associated with end-organ damage and increased cardiovascular risk. These data highlight the importance of RH and the need for an appropriate management. Nevertheless, little is known on the mechanisms responsible for RH and subjacent physiopathology. 3 Spironolactone, a mineralocorticoid antagonist, has demonstrated to be useful in the BP control in patients with RH 4, 5 being the most effective drug for the treatment of RH. 6 However, not all patients with RH respond to spironolactone, and negative effects should be taken into account (eg, a higher risk for hyperkalemia and associated complications). The identification of molecular indicators able to predict (anticipate) the response of a patient with RH to spironolactone treatment will contribute to optimize the rate of control of these patients.
As far as we know, no molecular data are available on RH. The metabolome is made up of the low molecular weight end products of the metabolism, representing the ultimate response of the body to a certain condition (eg, disease). Urine is a rich biofluid to investigate molecular alterations associated with renal physiology and kidney diseases. The metabolome was previously investigated in cardiovascular [7] [8] [9] and kidney diseases [10] [11] [12] [13] by our and other groups. However, few studies have been performed in the context of hypertension. [14] [15] [16] In this sense, we previously demonstrated that albuminuria development in hypertensives under chronic suppression of renin-angiotensin system is reflected in a metabolic profile in Abstract-Resistant hypertension (RH) affects 9% to 12% of hypertensive adults. Prolonged exposure to suboptimal blood pressure control results in end-organ damage and cardiovascular risk. Spironolactone is the most effective drug for treatment, but not all patients respond and side effects are not negligible. Little is known on the mechanisms responsible for RH. We aimed to identify metabolic alterations in urine. In addition, a potential capacity of metabolites to predict response to spironolactone was investigated. Urine was collected from 29 patients with RH and from a group of 13 subjects with pseudo-RH. For patients, samples were collected before and after spironolactone administration and were classified in responders (n=19) and nonresponders (n=10). Nuclear magnetic resonance was applied to identify altered metabolites and pathways. Metabolites were confirmed by liquid chromatography-mass spectrometry. Citric acid cycle was the pathway most significantly altered (P<0.0001). Metabolic concentrations were quantified and ranged from ng/mL malate to μg/mL citrate. Citrate and oxaloacetate increased in RH versus pseudoresistant. Together with α-ketoglutarate and malate, they were able to discriminate between responders and nonresponders, being the 4 metabolites increased in nonresponders.
Combined as a prediction panel, they showed receiver operating characteristic curve with area under the curve of 0.96. We show that citric acid cycle and deregulation of reactive oxygen species homeostasis control continue its activation after hypertension was developed. A metabolic panel showing alteration before spironolactone treatment and predicting future response of patients is shown. These molecular indicators will contribute optimizing the rate of control of RH patients with spironolactone. urine. 17 In this study, we investigate metabolic alterations subjacent to RH and the potential capacity of specific metabolites to predict response to spironolactone.
Methods

Patient Selection
We enrolled 42 patients arriving at the Hypertension Unit Hospital 12 de Octubre (recruitment period between July 2014 and March 2016). They were classified as RH if they fulfilled the following entry criteria: age ≥18 years and BP levels with mean values on a 24-hour ambulatory blood pressure monitoring (ABPM) >130/80 mm Hg while receiving ≥3 drugs at adequate doses (n=29). Patients with secondary hypertension were excluded. A 24-hour ABPM was performed at baseline to confirm that patients had true RH. Those patients with BP office levels >140/90 mm Hg (office) but 24-hour ABPM <130/80 mm Hg did not have true RH, and they are pseudoresistant hypertensive patients who were included as control group (hypertension; n=13). Controlled hypertension means hypertension normalized with treatment which is the case in pseudoresistant hypertensives. A prospective study was also conducted, intended to predict response to spironolactone. Patients with RH were treated with spironolactone 25/50 mg/d, added on top of former antihypertensive treatment. Response to spironolactone was defined to be effective if 24-hour ambulatory systolic BP dropped ≥20 mm Hg (responders [RHr], n=19). Metabolic alterations once spironolactone was administered were also evaluated, both in RHr and in nonresponders (RHnr, n=10). It is important to note that when patients are classified in RHr and RHnr, we refer to BP control and not to modulation of particular metabolites alterations. In every visit, a general questionnaire of wellbeing and potential side effects was usually made, and in no patient, it forced the interruption of the spironolactone administration nor even the decrease in the dose. Patients presenting alterations during the follow-up were not included in the study. In Table 1 , clinical characteristics of patients are shown. The study was conducted according to the recommendations of the Declaration of Helsinki, and it was approved by the local ethic committee, and all subjects gave informed consent.
BP Measurements
BP was measured at the office with a validated semiautomatic oscillometric device after 5-minute rest in a sitting position. BP values were estimated as the mean of 3 readings. Thereafter, 24-hour ABPM was performed using PaceLabs 90207 (SpaceLabs Inc., Redmond, WA) automated noninvasive oscillometric device, programmed to register BP at 20-minute intervals for the daytime period and at 30-minute intervals for the night-time period. The majority of measurements were performed on working days, and the patients were instructed to maintain their usual activities, return the following morning for device removal, and keep the arm extended and immobile at the time of each cuff inflation. Daytime and night-time periods were defined individually according to the patient self-reported data of going-to-bed and getting-up times.
Metabolic Alterations in RH: NMR Analysis of Urine Samples
First morning urine was collected, centrifuged, and supernatants were frozen at −80°C until processing. Metabolite analysis by 1 H nuclear magnetic resonance (NMR) was performed as previously described. 8, 11, 17 Briefly, thawed samples were diluted (1:1) in 200 mmol/L sodium phosphate buffer in D 2 O containing 0.01 mmol/L sodium trimethylsilyl propionate for chemical shift referencing. NMR experiments were performed at 277 K on a Bruker 700 MHz AVANCE III instrument equipped with a z axis gradient 5 mm triple resonance cryoprobe. Then, spectra were processed using TOPSPIN (version 1.3, Bruker Biospin Ltd) and analyzed using AMIX software (version 3.6.8, Bruker Rheinstetten, Germany). For this analysis, each spectrum was partitioned in variable sized spectral regions (buckets) according to a custom pattern developed specifically for the whole data set. Distribution of every bucket variable over the ensemble of spectra was evaluated by AMIX software for identification of discriminating variables (90% confidence level).
Those discriminating buckets resulting from both comparisons (controlled hypertension versus RH and RHr versus RHnr) were further considered together with their intensity in the NMR spectrum, and corresponding metabolites were assigned using Metabohunter web server. 18 Those metabolites altered in RH were submitted to an enrichment analysis looking for main pathways altered in RH by means of Metaboanalyst 3.0 tool. 19, 20 Pathways from the KEEG database showing P<0.05 and false discovery rate <0.05 were selected as significantly altered in the pathology.
Evaluation of Citric Acid Cycle in RH: Targeted Analysis by Mass Spectrometry
Individual metabolites taking part of the pathway found most significantly altered were measured in urine from patients (controlled hypertension and RH) for precise quantification by liquid chromatography coupled to mass spectrometry in selected reaction monitoring mode-LC-MS/MS. A 6460 Triple Quadrupole LC-MS/MS (1200 Series, Agilent Technologies) controlled by Mass Hunter Software (v4.0 Agilent Technologies) was used as previously published. 8, 17 Briefly, urine proteins were removed by organic precipitation, and separation took place at 0.4 mL/min in an acetonitrile gradient for 5 minutes in negative mode. Optimal conditions of analysis were established by analyzing commercial metabolite standards (Table S1 in the online-only Data Supplement). Quantitative determination of metabolites concentration was performed by individual calibration curves using commercial standards. The concentration range for each metabolite was established according to Human Metabolome Database values in urine, according to previous published data 21 and our experimental data in the specific samples included in the study. All curves were fit to linear regression mode, and the individual values of each urine sample (each sample measured in triplicate) were then interpolated using GraphPad software. Normalization was performed by creatinine value of each urine sample, and metabolite concentration was expressed in (μmol/L)/ (mmol/L) creatinine.
Prediction of Response to Spironolactone and Metabolic Effect After Treatment
Subjacent metabolic changes in RH were investigated by comparing controlled hypertension and RH patients as described above. In addition, a pilot prospective study was performed to evaluate a potential capacity of identified metabolites to predict response to treatment with spironolactone. For that, urine samples were collected before administration of spironolactone and classified according to patient response in RHr and RHnr. Metabolites were analyzed by selected reaction monitoring mode-LC-MS/MS, as described.
Urine samples were also collected after treatment to additionally evaluate the impact of spironolactone on identified metabolites, both in RHr and RHnr, referred as RHr-post and RHnr-post, respectively. Metabolites in these urine samples were analyzed by selected reaction monitoring mode-LC-MS/MS as described.
Statistical Analysis
To identify significant differences in clinical characteristics or medication, patients groups were compared by nonparametric MannWhitney test with 95% confidence level. To calculate statistically significant differences in metabolite concentrations between groups (targeted analysis), we first applied the ROUT method (robust regression and outlier removal) to detect outliers based on the false discovery rate, setting the Q value to 5%. A nonparametric Mann-Whitney test with 95% confidence level was then performed by means of GraphPad Prism 6 (version 6.01) software. For those metabolites showing alteration between RHr and RHnr, a combined receiver operating characteristic (ROC) curve was performed to evaluate their predictor potential. The multivariate ROC curve was performed using Random Forest as classification and built-in method. Values are expressed as percentage (%) or mean±SD (except for ACR expressed as median±interquartile range). ACEi indicates angiotensinconverting enzyme inhibitor; ACR, albumin/creatinine; ARB, angiotensin receptor blocker; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HTN, pseudoresistant hypertensive patients who were included as control group; LDL, low-density lipoprotein; MDRD, Modification of Diet in Renal Disease; RH, resistant hypertension; RHr, resistant hypertension patients responders to spironolactone treatment; RHnr, resistant hypertension patients nonresponders to spironolactone treatment; and SBP, systolic blood pressure.
Results
Coordinated Metabolic Response in RH: Citric Acid Cycle Changes
The statistical analysis performed on the NMR data resulted in a total of 7 chemical shifts consisting in 1.48, 1.99, 2.08, 2.42, 4.52, 4.72, and 7.37 ppm. Three KEGG metabolic pathways resulted significantly altered (see P value and false discovery rate limits in Table S2 ): citric acid cycle (CAC), pyruvate metabolism, and gluconeogenesis. All of them are energyrelated processes, and they are interconnected. CAC (KEGG: hsa00020) highlights with a false discovery rate=0.0024 and a P<0.0001.
The main metabolites of CAC are acetyl coenzyme A, oxaloacetate, citrate, isocitrate, α-ketoglutarate, succinyl coenzyme A, succinate, and malate. Because according to Human Metabolome Database there is not data for coenzymes presence in urine, we focused on the rest for further analysis together with pyruvate as precursor of acetyl coenzyme A. Metabolites were quantitatively analyzed, and the equations of the linear fit for each metabolite, the concentration range, and the square of the correlation coefficient values (R 2 ) can be found in Figure S1 . As summary, all the curves present a goodness to fit higher that 0.98 and in most cases higher to 0.99 in terms of R 2 . The ranges went from ng/mL in the case of malate, the less concentrated in urine, to μg/mL for citrate, the most concentrated one. The final value of the concentration was corrected by the value of the creatinine in each sample resulting in concentration values in (μmol/L)/(mmol/L) creatinine as it is presented in Table 2 .
The concentration levels of the different metabolites quantified in urine were used to evaluate the differences between the clinical groups. Those metabolites corresponding to RH are presented in Figure 1 integrated in the pathway. Citrate and oxaloacetate are increased in patients presenting RH versus those with controlled hypertension, being able to discriminate the 2 groups (citrate, P=0.0390; oxaloacetate, P=0.0146). These 2 metabolites, together with α-ketoglutarate and malate, show differences between patients with RH, depending on their future response to spironolactone. They are able to discriminate between RHr and RHnr, being the 4 metabolites increased in RHnr (citrate, P=0.0471; α-ketoglutarate, P=0.0186; malate, P=0.0382; and oxaloacetate, P=0.0120). The 4 metabolic responses were evaluated as prediction panel, individually and combined. Figure 2A shows how the predictive accuracy increased with the number of metabolites included in the model. The prediction overview shows the predicted class probabilities (x axis) of each sample (y axis). The probability scores range from 0 to 1. Less than 0.5 will belong to 1 group (RHr) and >0.5 belong to the other group (RHnr). When the 4 metabolites were combined, the predicted class graph shows good separation between RHr and RHnr ( Figure 2B ). The ROC curve provides complete and easily visualized sensitivity/specificity. In an ROC curve, the true positive rate (sensitivity) is plotted in function of the falsepositive rate (1-specificity). The closer the ROC curve is to the upper left corner, the higher the overall accuracy of the test. The area under the ROC curve is a measure of how well the maker panel can distinguish between the 2 groups (RHr/ RHnr). In this model, the ROC curve results in area under the curve=0.96 ( Figure 2C ).
Metabolite Alterations Under Spironolactone Treatment
When metabolites concentrations were evaluated in the urine of patients before and after spironolactone treatment, citrate, malate, and oxaloacetate were significantly altered as it is shown in Figure 3 . Citrate concentration was maintained with the treatment in RHr patients, but their levels are decreased in RHnr patients (P=0.0015). In the case of malate, all patients lower their levels after the spironolactone treatment, being this change higher in RHnr (RHr patients P=0.0336; RHnr patients P<0.0001). For oxaloacetate, we found an effect on RHr patients, with levels increasing after the administration of spironolactone (P=0.0116)
Discussion
Inadequate control of BP facilitates cardiovascular and renal damage. 22 In patients with RH, BP continues uncontrolled despite therapeutic intervention following recommended guidelines. Prevention of RH depends on adequate treatment which should be applied early in time and aggressively. However, a considerable number of hypertensive patients HMDB indicates human metabolome database; HTN, controlled hypertension; RH, resistant hypertension; RHr, patients with RH responders to spironolactone (urine collected before treatment); RHr-post, patients with RH responders to spironolactone (urine collected after treatment); RHnr, patients with RH nonresponders to spironolactone (urine collected before treatment); RHnr-post, patients with RH nonresponders to spironolactone (urine collected after treatment).
RH vs HTN: *P<0.05; RHr vs RHnr: †P<0.05, ‡P<0.01.
develop RH. RH is controlled in a high percentage of cases with aldosterone blockers. Spironolactone administration is the first choice and may be effective in difficult-to-treat patients, 6 causing a decrease in BP in 22/10 mm Hg in the ASCOT study 23 or 9.8/1.0 mm Hg in the ASPIRANT study. 24 Unfortunately, response to treatment is not guaranteed, and adverse effects may not be negligible, in particular gynecomastia or breast discomfort and biochemical abnormalities (mainly hyperkaliemia). Currently, molecular clues about RH development are inexistent, and physiopathological mechanisms subjacent to RH are unknown. In this study, we first investigated most significant metabolic alterations in RH by comparing urine samples from patients with RH (confirmed by ABPM) and controlled hypertensives as control group. In a second stage, we investigated a potential prediction capacity of identified metabolites by anticipating patients' response to spironolactone. For that, we analyzed urine samples from RHr and RHnr collected before Combined metabolic responses for citrate, α-ketoglutarate, malate, and oxaloacetate were evaluated as prediction model for response to spironolactone. The predictive accuracy graph (A) shows how it increases with the number of metabolites included. The predicted class graph is shown in (B) and the resulting reactive oxygen species curve is shown in (C). AUC indicates area under the curve; CI, confidence interval; RHr, resistant hypertension patients responders to spironolactone treatment; and RHnr, resistant hypertension patients nonresponders to spironolactone treatment.
spironolactone was administered. Effect of the treatment on metabolic pattern was also evaluated in urine collected at 2 months after administration.
An enrichment analysis of metabolites detected in urine samples from patients with RH pointed to dysregulation of the CAC. The CAC is responsible for generating energy through the oxidation of acetyl coenzyme A, taking part mainly in the mitochondria. However, the efforts dedicated to assess the participation of the energy metabolism and energy metabolism dysfunction on hypertension have been limited. In this sense, increased mitochondrial function was found in spontaneously hypertensive rats compared with normotensives with pyruvate dehydrogenase complex activity consistently higher, indicating a higher rate of pyruvate flux into the CAC, and increase of BP was also observed when pyruvate dehydrogenase activity was increased. 25 However, higher fumarase activity, an enzyme that catalyzes deconversion of fumarate to malate, was suggested to protect from hypertension, fumarate excess exacerbated saltinduced hypertension, and a hypertensive effect was observed linked to a succinate excess, a metabolite upstream from fumarate in the CAC. 25, 26 Recently, serum pyruvate analyzed by NMR was correlated with BP, 27 and it has also been described that CAC activity is increased 28 and that an accumulation of CAC intermediates could result in a pseudohypoxic state. 26 Evidence also suggests that kidney ischemia may be responsible for sympathetic nervous system activation in renal hypertension. 29 In this study focused in patients with RH, we show that the CAC continues its activation after hypertension was developed.
Mitochondria are a major site of reactive oxygen species (ROS) production but also a possible relevant target of ROS action. Oxidative stress is provoked by impairment in ROS production and metabolism, which may result in ultimate cellular dysfunction and damage. It can be cause, consequence, or a potentiating factor for hypertension. Increased ROS have been reported in the kidney in hypertension models, 26, 30 and ROS generated in the renal and vascular systems are implicated in pathological signaling leading to hypertension. 31, 32 Among ROS, H 2 O 2 is one of the major signaling molecules involved in pathophysiological processes. H 2 O 2 has prohypertensive effects because increased vasoconstriction, decreased dieresis and natriuresis, and control of renal medullary H 2 O 2 levels have been proposed as target in future treatments of hypertension. 33 It has been shown that CAC is modulated to control intracellular concentration of ROS, being able to control oxidizing moieties formation but also to participate in their decomposition. 34 In particular, ketoglutarate is a potent ROS scavenger, and the modulation of redox environment is partly achieved by increased production of ketoglutarate and decreased use via the CAC. 35 In our study, intracellular metabolism was not investigated. However, metabolites identified in urine are in any case the end products of altered metabolism in RH, which can be considered as messengers from the physiopathological status of the organisms and, ultimately, molecular signatures that may help in anticipating patient prognosis. In this sense, ketoglutarate is one of the metabolites showing significant increase in patients not responding to spironolactone versus RHr, in agreement with CAC deregulation in ROS homeostasis control. The same variation trend was observed for oxaloacetate, pointing to the same mechanism of cellular ROS modulation.
36 Surprisingly, spironolactone administration caused higher levels for this metabolite only in responders despite of the positive effect for this drug in BP control. It can be hypothesized that this metabolite has a beneficial effect, showing increased levels both in RH versus controlled hypertension, in RHnr versus RHr, and after spironolactone administration in those individuals who respond, as part of a compensatory mechanism being or not completely successful. Citrate is a metabolic substrate in the kidneys, and urinary citrate levels were found increased in systemic alkalosis, which is common in patients with RH and in line with data shown here. 37 Also, citrate accumulation in urine from patients with RH was higher in those who will not respond to spironolactone in the future and diminished significantly once spironolactone was administered. The same trend was observed for malate, both for RHr and RHnr. The observed reduction of citrate and malate could be a consequence of hyperkalemia or other related effects of spironolactone. Recently, it was shown how preischemic administration of an inhibitor of the malate-aspartate shuttle provides cardioprotection against ischemia/reperfusion injury although with unknown mechanism, in agreement with mitochondrial function deregulation in vascular injury. 38 The observed metabolites accumulation in urine can be associated with a hypoxic state. Hypoxia is related with mitochondrial dysfunction and because of that with several diseases, including cardiovascular complications. 39 Furthermore, when the hypoxia is chronic, it may cause a marked activation of the sympathetic Figure 3 . Effect of spironolactone treatment on citrate, malate, and oxaloacetate. Urine samples were collected before spironolactone administration. For urine samples collected after spironolactone treatment, RHr-post and RHnr-post correspond to responders and nonresponders, respectively. RHr indicates resistant hypertension patients responders to spironolactone treatment; and RHnr, resistant hypertension patients nonresponders to spironolactone treatment.
nervous systemin healthy humans and increase the systemic arterial pressure. 40 The increased sympathetic nervous system activity is one of the few known underlying conditions of RH, supporting a crucial role in the resistance to antihypertensive treatments. 3 However, it is known that hypoxia can produce oxidative stress by a decrease in electron transport and an increase in ROS. 39, 41 This impairment in the electron transport chain can be also related to changes in BP. 26 In general, the RHnr have a more marked decrease or a blunted increase in CAC metabolites after receiving spironolactone (while they do not respond with a decrease in BP), suggesting that these metabolites may be used as markers but are not directly participating to the BP response to spironolactone. However, in view of reported metabolic changes, it can be hypothesized that RHnr may exhibit more severe metabolic dysfunction than RHr as the metabolites either vary between controlled hypertension and RH and also in RHnr versus RHr (oxaloacetate, citrate), or they show no significant variation between controlled hypertension and RH but they do in RHnr versus RHr (malate, ketoglutarate).
The study fulfilled the requirements of an Omics study in terms of group size and technical workflow. 42 However, the main limitation is the low number of patients from a clinical point of view. Thus, the clinical usefulness of the metabolites here reported should be replicated in larger multicenter cohorts to further confirm whether the same pathways and treatment results could be replicated.
Perspectives
This is the first study to identify metabolic changes reflected in urine subjacent to RH. The urinary metabolome was explored, and individual metabolites were quantified by mass spectrometry, a technique that can be easily implemented in daily routine clinical practice. CAC was the most significant alteration with specific metabolites showing capacity to anticipate spironolactone response. This means that the measurement of this specific metabolic signature in urine, collected before drug administration, differentiates those individuals who will not respond to spironolactone in terms of BP control. This finding is of great importance in the control of patients with RH and opens a new field of research in which the CAC is shown to be involved.
